![Javier San Martin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 146 002 $ in data 30/06/2026
Attualmente, Javier San Martin è Chief Medical Officer presso Arrowhead Pharmaceuticals, Inc. In precedenza ha ricoperto la posizione di direttore esecutivo dell'area terapeutica dell'osso presso Amgen, Inc, Principal presso Eli Lilly & Co, Senior VP-Global Clinical Development presso Ultragenyx Pharmaceutical, Inc e Senior Vice President-Clinical Development presso Alder Biopharmaceuticals, Inc. Ha ricevuto un dottorato dalla Universidad de Buenos Aires.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
LEONABIO, INC. 0,17% | 01/05/2026 | 15.887 ( 0,17% ) | 146 002 $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| LEONABIO, INC. | Direttore Tecnico/Scientifico/R&S | 15/04/2024 |
| Società | Posizione | Fine |
|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 01/02/2024 |
| ULTRAGENYX PHARMACEUTICAL INC. | Corporate Officer/Principal | 01/11/2019 |
| AMGEN INC. | Corporate Officer/Principal | - |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
| ALDER BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 7 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Eli Lilly & Co.
 Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
Arrowhead Pharmaceuticals, Inc.
 Arrowhead Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel drugs to treat intractable diseases | Health Technology |
Ultragenyx Pharmaceutical, Inc.
 Ultragenyx Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel products for the treatment of serious rare and ultra-rare genetic diseases | Health Technology |
LeonaBio, Inc.
 LeonaBio, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that specializes in research and develops transformative therapies for brain diseases | Health Technology |
University of Buenos Aires School of Medicine
 University of Buenos Aires School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
